Shares of Novo Nordisk A/S (ADR) (NYSE:NVO) ended Wednesday session in red amid volatile trading. The shares closed down -0.68 points or -1.18% at $56.83 with 1,186,036 shares getting traded. Post opening the session at $56.62, the shares hit an intraday low of $56.47 and an intraday high of $56.97 and the price vacillated in this range throughout the day. The company has a market cap of $118.76 billion and the numbers of outstanding shares have been calculated to be 2.06 billion shares.
Novo Nordisk A/S (ADR) (NVO) engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents in North America, Europe, Japan and South Korea, China, Hong Kong, Taiwan, and other countries. Novo Nordisk A/S has a collaboration agreement with the Langer Laboratory. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Shares of Novartis AG (ADR) (NYSE:NVS) ended Wednesday session in red amid volatile trading. The shares closed down -0.40 points or -0.52% at $76.56 with 1,767,480 shares getting traded. Post opening the session at $76.73, the shares hit an intraday low of $76.05 and an intraday high of $76.81 and the price vacillated in this range throughout the day. The company has a market cap of $206.72 billion and the numbers of outstanding shares have been calculated to be 2.37 billion shares.
Novartis AG (ADR) (NVS) develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Shares of Opko Health Inc. (NYSE:OPK) ended Wednesday session in green amid volatile trading. The shares closed up +0.10 points or 0.96% at $11.03 with 2,441,408 shares getting traded. Post opening the session at $11.03, the shares hit an intraday low of $10.91 and an intraday high of $11.10 and the price vacillated in this range throughout the day. The company has a market cap of $5.96 billion and the numbers of outstanding shares have been calculated to be 545.84 million shares.
Opko Health Inc. (OPK) on March 28, 2016 announced the appointment of Dr. Ronald Trust as Vice President of Regulatory Affairs of OPKO Pharmaceuticals.
Prior to joining OPKO, Ron held senior regulatory positions at Allergan (through its acquisition of Durata Therapeutics), spent over 16 years at Pfizer in various regulatory affairs positions, and most recently worked as an independent consultant providing strategic regulatory consulting services to the pharmaceutical industry. Ron received his PhD in organic chemistry from the California Institute of Technology and he also holds a Masters in Business Administration from Fairleigh Dickinson University.
“Ron has over 40 years of pharmaceutical industry development experience, including over 30 years in regulatory affairs, safety/risk management and quality assurance, which will be of tremendous value as we continue to bring our product candidates to market,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.